Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
This was a non-confirmatory, randomized, participant- and investigator-blinded, placebo-controlled, single ascending dose study to investigate the safety, tolerability and PK of LNA043 in Japanese participants with osteoarthritis of the knee. This study consisted of 2 cohorts with a total of 12 participants.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female Japanese participants aged 20 to 80 years at screening
A body mass index (BMI) 16.0 kg/m2 or more but less than 35.0 kg/m2 at screening
Established diagnosis of primary tibio-femoral osteoarthritis of the target knee by standard American College of Rheumatology (ACR) criteria for at least 6 months prior to screening (clinical and radiological criteria).
You may not be if
Partial or complete joint replacement in the target knee. Planned knee surgery for either knee during the study.
Arthroscopy of the target knee within 6 months prior to Screening or planned during the study
Use of electrotherapy, acupuncture, and/or chiropractic treatments for osteoarthritis of the knee within 4 weeks prior to screening
Malalignment \>10° in the target knee (varus/valgus)